The German biopharmaceutical company CureVac has begun the clinical trial of its candidate vaccine against coronavirus in Peru. Thus, it has invited people —over 18 years of age, in good health, and who have not tested positive for COVID-19— for the research.
To recruit volunteers in the South American country, CureVac will conduct a survey developed by clinical researchers.
Within this framework, the laboratory expects the participation of more than 35,000 volunteers —most of them in Europe and Latin America.
Participants will pass general health check-ups and receive close medical follow-up evaluations.
Additionally, upon completion of the messenger RNA vaccine clinical trial, participants will continue to be monitored in a one-year extension study as they continue their normal activities.
It is worth mentioning that the CureVac trial is randomized, blind, and placebo-controlled. It will evaluate the safety and efficacy of its vaccine in adults at a 12 ug dose.
If you are over 18 years old, in good health and have not tested positive for COVID-19 (swab test), you can contact the organizers to participate in the clinical trials by calling (+51) 901 006 085 and (+51) 919 473 041 or via email:
herald.upch@gmail.com.
As is known, the German pharmaceutical company hopes to have its own vaccine ready and authorized for distribution throughout 2021, the production of which would be less expensive than that developed by
Pfizer and BioNTech.